Kadimastem Ltd
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a cli… Read more
Kadimastem Ltd (KMSTF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.015x
Based on the latest financial reports, Kadimastem Ltd (KMSTF) has a cash flow conversion efficiency ratio of 0.015x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-744.55K) by net assets ($-50.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kadimastem Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Kadimastem Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kadimastem Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kadimastem Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wellgistics Health, Inc. Common Stock
NASDAQ:WGRX
|
-0.168x |
|
Rohas Tecnic Bhd
KLSE:9741
|
0.041x |
|
Dc Infotech And Communication Limited
NSE:DCI
|
0.004x |
|
Auriginal Mining Corp.
V:AUME
|
-0.021x |
|
Mycodern S.A.
F:GY3
|
N/A |
|
HF COMPANY INH. EO -50
F:HFC
|
N/A |
|
Inter-Rock Minerals Inc
PINK:IRCKF
|
0.238x |
|
Enduro Metals Corporation
OTCQB:ENDMF
|
-0.023x |
Annual Cash Flow Conversion Efficiency for Kadimastem Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Kadimastem Ltd from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-29.15 Million | $-2.75 Million | 0.095x | -96.28% |
| 2023-12-31 | $-4.36 Million | $-11.09 Million | 2.543x | +104.15% |
| 2022-12-31 | $326.00K | $-20.00 Million | -61.337x | -4278.97% |
| 2021-12-31 | $15.38 Million | $-21.55 Million | -1.401x | -151.73% |
| 2020-12-31 | $-8.06 Million | $-21.83 Million | 2.708x | +54.11% |
| 2019-12-31 | $-12.03 Million | $-21.13 Million | 1.757x | +156.84% |
| 2018-12-31 | $6.74 Million | $-20.83 Million | -3.091x | +33.28% |
| 2017-12-31 | $4.28 Million | $-19.83 Million | -4.633x | -390.73% |
| 2016-12-31 | $-8.56 Million | $-13.63 Million | 1.594x | -85.47% |
| 2015-12-31 | $-1.02 Million | $-11.22 Million | 10.967x | +273.45% |
| 2014-12-31 | $1.55 Million | $-9.78 Million | -6.323x | -307.26% |
| 2013-12-31 | $8.69 Million | $-13.48 Million | -1.552x | -149.13% |
| 2012-12-31 | $-2.73K | $-8.63K | 3.160x | -- |